ArticleNature biotechnology2020
Author Correction: A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy.
Article in Nature biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mathematical models and computational approaches in CAR-T therapeutics.Frontiers in immunology · 2025Review
- Opportunities and challenges in design and optimization of protein function.Nature reviews. Molecular cell biology · 2024Review
- Rational Design of Chemically Controlled Antibodies and Protein Therapeutics.ACS chemical biology · 2023Article
- CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues.Frontiers in immunology · 2022Article
Corrections and comments
- Erratum for
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Identifiers
32127717What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.